SEMA3A and metabolic dysfunction-associated steatotic liver disease: Both, in animal models for MASLD (with or without diabetes) and in primary human LSECs (from both male and female donors) treated with palmitic acid, expression of Sema3a/SEMA3A is substantially enhanced, revealing how this defenestrating (angiocrine) signal is induced by DIO.